Already a member?
Login
Become a member
Register
Home
About
About PCSK9 Forum
Editorial Board
Mission Statement
About PCSK9
What are PCSK9 inhibitors?
Why are new treatments needed?
Which patients may benefit?
News
News
Meeting Reports
Expert Meetings
Commentary
Hot topics
From the Editors
Questions of the Month
Slides
Slide resource programme
Slides by Editorial Board
Trials
Videos
Resources
Trials
Slides by Editorial Board
Events
Videos
Webcasts
Guidelines & Consensus Guidance
Article Archive
Contact
⇒ Main Menu
Home
About
– About PCSK9 Forum
– Editorial Board
– Mission Statement
– What are PCSK9 inhibitors?
– Why are new treatments needed?
– Which patients may benefit?
News
– News
– Meeting Reports
– Expert Meetings
– Hot topics
– From the Editors
– Questions of the Month
Slides
– Slide resource programme
– Slides by Editorial Board
Trials
Videos
Resources
– Trials
– Slides by Editorial Board
– Events
– Videos
– Webcasts
– Guidelines & Consensus Guidance
– Article Archive
Contact
News
SANTORINI data support PCSK9i combinations for high risk patients
High Lp(a) linked to plaque progression over 10 years
PERI-DYS study suggests need for greater LLT intensification
Latest insights from CLEAR Outcomes
Phase 2b data show benefits of oral MK-0616 in hypercholesterolaemia
YELLOW III supports aggressive lipid lowering to reduce plaque progression
Latest News Updates
COMING SOON: PCSK9 slide resources – FOURIER, ODYSSEY OUTCOMES and more
Posted on
19 March 2019
|
Related content